INDP
Indaptus Therapeutics Inc

15,842
Loading...
Loading...
News
all
press releases
Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...
Globe Newswire·1y ago
News Placeholder
More News
News Placeholder
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting
Data demonstrates that Company's Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses New data shows activity in M1 macrophages, natural...
Globe Newswire·1y ago
News Placeholder
Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024
Tribe Public Webinar with Indaptus Therapeutics Tribe Public Webinar with Indaptus Therapeutics Fully Engaging The Human Immune System To Cure Disease, Featuring CEO, Jeffrey...
Globe Newswire·2y ago
News Placeholder
Indaptus Therapeutics: Q4 Earnings Insights
read more...
Benzinga·2y ago
News Placeholder
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 Initiating Multi-Dosing for patients with solid tumors NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus...
Globe Newswire·2y ago
News Placeholder
Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Increases By 18.6%
Indaptus Therapeutics, Inc. (NASDAQ:INDP Get Free Report) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 17,200...
Zolmax·2y ago
News Placeholder
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to recommend initiating multi-dosing cohort Single dose cohort data...
Globe Newswire·2y ago
News Placeholder
12 titres de soins de sant en mouvement lors de la session apr s-cl ture le 01/03/2024
Gagnants Le titre Ainos (NASDAQ:AIMD) a mont vendredi de 54,28% 1,62 dollars lors de la session after-market. Le titre Aadi Bioscience (NASDAQ:AADI) a grimp de 27,60% 2,45 dollars. Le titre...
Benzinga·2y ago
News Placeholder
Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference
NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...
Globe Newswire·2y ago
News Placeholder
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...
Globe Newswire·2y ago

Latest INDP News

View

Advertisement. Remove ads.

Advertisement. Remove ads.